Replimune Presents Major Evaluation Information from IGNYTE Medical Trial of RP1 Mixed with Nivolumab in Anti-PD1 Failed Melanoma at European Society for Medical Oncology (ESMO) Congress 2024
Information from the IGNYTE major evaluation exhibits clinically significant exercise throughout all subgroups, together with those that had obtained prior ...
